The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
暂无分享,去创建一个
Benjamin J. Raphael | Lee T. Sam | Gregory A. Ryslik | S. Dhanasekaran | K. Pienta | A. Chinnaiyan | Fabio Vandin | I. Asangani | N. Palanisamy | D. Rhodes | S. Tomlins | R. Mehra | Xuhong Cao | J. Prensner | D. Robinson | J. Siddiqui | Xiaojun Jing | Amjad P. Khan | S. Chun | M. Quist | C. Grasso | Yi-Mi Wu | Bushra Ateeq | R. Lonigro | L. Kunju | J. Brenner | Matt Anstett | John R. Prensner | X. Jing | L. Sam
[1] J. Brooks,et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness , 2012, Oncogene.
[2] J. Lindberg,et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer , 2012, Oncogene.
[3] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[4] Arul M Chinnaiyan,et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. , 2011, Neoplasia.
[5] Wei Li,et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. , 2011, Cancer research.
[6] Peter C. Hollenhorst,et al. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. , 2011, Genes & development.
[7] O. Kallioniemi,et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer , 2011, The EMBO journal.
[8] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[9] Huanming Yang,et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.
[10] Hongtao Yu,et al. Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.
[11] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[12] S. Dhanasekaran,et al. Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.
[13] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[14] C. Glass,et al. Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.
[15] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[16] Gerald C. Chu,et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.
[17] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[18] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[19] K. Pienta,et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.
[20] H. Timmers,et al. Histone lysine methylation and demethylation pathways in cancer. , 2011, Biochimica et biophysica acta.
[21] J. Lis,et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. , 2010, Genes & development.
[22] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[23] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[24] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[25] M. Shen,et al. Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.
[26] Takahito Hara,et al. Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.
[27] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[28] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[29] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[30] Andrew R. Gehrke,et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.
[31] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[32] Eli Upfal,et al. Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.
[33] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[34] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[35] Mingming Jia,et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..
[36] Ryan D. Morin,et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.
[37] A. Ashworth,et al. CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. , 2009, Carcinogenesis.
[38] B. Trask,et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. , 2009, Cancer research.
[39] M. Rubin,et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.
[40] Johann S de Bono,et al. Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.
[41] Clifford A. Meyer,et al. Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.
[42] D. Olmos,et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.
[43] Daniel Birnbaum,et al. Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.
[44] K. Ohashi,et al. MST2- and Furry-Mediated Activation of NDR1 Kinase Is Critical for Precise Alignment of Mitotic Chromosomes , 2009, Current Biology.
[45] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[46] M. Gerstein,et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer , 2009, Genes, chromosomes & cancer.
[47] Bin Tean Teh,et al. Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.
[48] J. Stamatoyannopoulos,et al. Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.
[49] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..
[50] M. Dimopoulos,et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication , 2009, International journal of cancer.
[51] Emily H Turner,et al. Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.
[52] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[53] S. Varambally,et al. Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.
[54] F. Leisch,et al. FlexMix Version 2: Finite Mixtures with Concomitant Variables and Varying and Constant Parameters , 2008 .
[55] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[56] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[57] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[58] S. Serrano,et al. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations , 2008, Modern Pathology.
[59] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[60] R. Shah,et al. CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .
[61] Clifford A. Meyer,et al. FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.
[62] R. Shah,et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.
[63] Robyn L Prueitt,et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.
[64] D. Turner,et al. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer , 2008, Expert review of anticancer therapy.
[65] S. Varambally,et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.
[66] H. Klocker,et al. Plexin-B1 mutations in prostate cancer. , 2008, Proceedings of the National Academy of Sciences of the United States of America.
[67] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[68] Guy Cavet,et al. Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.
[69] S. Dhanasekaran,et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. , 2007, Cancer research.
[70] K. Pienta,et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.
[71] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[72] Yusuke Nakamura,et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.
[73] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[74] J. Tchinda,et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. , 2007, Neoplasia.
[75] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[76] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[77] Yi-jun Zhu,et al. Identification of the MLL2 Complex as a Coactivator for Estrogen Receptor α* , 2006, Journal of Biological Chemistry.
[78] A. Evans,et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.
[79] Pengbo Liu,et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.
[80] Jin-Tang Dong. Prevalent mutations in prostate cancer , 2006, Journal of cellular biochemistry.
[81] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[82] J. Mirosevich,et al. Foxa1 and Foxa2 Interact with the Androgen Receptor to Regulate Prostate and Epididymal Genes Differentially , 2005, Annals of the New York Academy of Sciences.
[83] Yutaka Miura,et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer , 2005, Nature Genetics.
[84] Tony Pawson,et al. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer , 2004, Nature Genetics.
[85] M. Becich,et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] Paul Tempst,et al. PINdb: a database of nuclear protein complexes from human and yeast , 2004, Bioinform..
[87] W. Gerald,et al. Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.
[88] R. Tibshirani,et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[89] Renjie Jin,et al. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. , 2003, Molecular endocrinology.
[90] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[91] E. Latulippe,et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.
[92] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[93] S. Friedman,et al. KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer , 2001, Science.
[94] J. Welsh,et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.
[95] Donna M. Peehl,et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.
[96] K. Pienta,et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[97] A. Gronenborn,et al. Correction of the NMR structure of the ETS1/DNA complex , 1997, Journal of biomolecular NMR.
[98] K. Hamil,et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.
[99] J. Moul,et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.